SCHEMBL6707975

SCHEMBL6707975

O=C(Nc1ccccn1)c1conc1C1CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 10/20 0.49
RAB9A P51151 10/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.46
PKM P14618 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX15 P16050 1/20 0.45
HIF1A Q16665 1/20 0.45
KCNMA1 Q12791 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709044 0.79 L3MBTL1 (0.59) MEN1KMT2AL3MBTL1KDM4ENPC1
SCHEMBL6707253 0.78 MEN1 (0.52) MEN1KMT2AL3MBTL1KDM4ENPC1
SCHEMBL1003875 0.76 ALDH1A1 (0.51) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL6707940 0.72 NPC1 (0.52) MEN1KMT2AL3MBTL1KDM4ENPC1
SCHEMBL6707256 0.72 MEN1 (0.52) MEN1KMT2AL3MBTL1KDM4ENPC1
SCHEMBL1003175 0.72 SORT1 (0.50) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL6707303 0.70 ALDH1A1 (0.46) MEN1KMT2AL3MBTL1KDM4ENPC1
SCHEMBL932926 0.69 MAPT (0.40) KMT2AKDM4ECHRNA4SMN1; SMN2ALDH1A1
SCHEMBL22246801 0.69 RAB9A (0.41) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL17675194 0.68 MEN1 (0.71) MEN1KMT2AL3MBTL1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders SUGEN, INC. 2004-05-27 US disclosed
US-6649635-B2 For therapy of cancer SUGEN, INC. 2003-11-18 US disclosed
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders MCMAHON GERALD (US) 2002-05-30 US disclosed
EP-1012150-A4 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN INC (US) 2002-05-29 EP disclosed
US-6316479-B1 ANTICANCER AGENTS SUGEN, INC. 2001-11-13 US disclosed
EP-1012150-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS Sugen, Inc. (US) 2000-06-28 EP disclosed
WO-1998052944-A1 HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS SUGEN, INC. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065283-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC MEN1 3182/4885KMT2A 607/4885L3MBTL1 1271/4885
US-20040102489-A1 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders ABL1, ERBB2, PRKDC MEN1 3182/4885KMT2A 607/4885L3MBTL1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.